Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Recruiting
Phase 2
Interventional Study
Appendiceal Mucinous Neoplasm
Pseudomyxoma Peritonei
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 15 (estimated)
- Sponsor
- University of California, Irvine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria (complete details available in protocol):
* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy …
Contacts
Chao Family Comprehensive Cancer Center University of California, Irvine
1-877-827-8839
CONTACT
University of California Irvine Medical
CONTACT